Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 781 to 795 of 2042 results for guidelines

  1. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

  2. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

  3. Kidney conditions: CKD urine albumin:creatinine ratio (IND144)

    This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109

  4. Committee C members

    on a NICE guideline update committee (NG88, 2018) and a specialist lay member of a quality standards advisory committee for the same...

  5. Therapeutic interventions after abuse and neglect

    them in decisions about their life. Useful links NICE guideline: Child abuse and neglect (NG76) . Additional information about...

  6. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 16 July 2025

  7. Hospital care

    NICE's impact on hospital stays, delays in leaving hospital and independent living

  8. Heart Failure: ACEi or ARBs (IND193)

    This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with an ACE-I or ARB. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM172

  9. Implanting a baroreceptor stimulation device for resistant hypertension

    In development [GID-IP1180] Expected publication date: TBC

  10. Our programmes

    The different types of health, public health and social care information provided by NICE.

  11. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)

    This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.

  12. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

      Status ...

  13. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  14. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

  15. Bronchial thermoplasty for severe asthma (IPG635)

    Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.